Clinical Trials
227
Active:12
Completed:72
Trial Phases
5 Phases
Phase 1:33
Phase 2:75
Phase 3:55
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (213 trials with phase data)• Click on a phase to view related trials
Phase 2
75 (35.2%)Phase 3
55 (25.8%)Not Applicable
49 (23.0%)Phase 1
33 (15.5%)Phase 4
1 (0.5%)A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
Not Applicable
Not yet recruiting
- Conditions
- Leukemia, B-Cell, ChronicLeukemia
- Interventions
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 262
- Registration Number
- NCT07082452
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
Phase 2
Recruiting
- Conditions
- Metastatic/Locally Advanced Small-Cell Lung CancerMetastatic/Locally Advanced Poorly Differentiated NECMetastatic/Locally Advanced High-grade MTC
- Interventions
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 40
- Registration Number
- NCT07016230
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 162
- Registration Number
- NCT07001618
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood
Not Applicable
Not yet recruiting
- Conditions
- Ototoxicity, Drug-InducedOtotoxicity, Radiation-InducedPediatric Cancer
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 500
- Registration Number
- NCT06957132
- Locations
- 🇫🇷
Hôpital Necker, Paris, France
🇫🇷Institut Curie, Paris, France
🇫🇷Gustave Roussy, Villejuif, France
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Phase 4
Not yet recruiting
- Conditions
- Kidney CancerRenal Cell Cancer
- Interventions
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 50
- Registration Number
- NCT06934057
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest - Angers, Angers, France
🇫🇷Centre Georges François Leclerc, Dijon, France
🇫🇷Centre Léon Bérard, Lyon, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 46
- Next
News
No news found